Trial Radar AI | ||
|---|---|---|
Clinical Trial NCT05839275 (IRIS) for High-Risk Localized Soft Tissue Sarcoma is recruiting. See the Trial Radar Card View and AI discovery tools for all the details. Or ask anything here. | ||
Fudan UniversityThe Combination of Radiotherapy，Surufatinib and Sintilimab in High-Risk Localized Soft Tissue Sarcoma (IRIS) Phase 1, Phase 2 52
There will be 52 patients with high-risk localized extremity and trunck soft tissue sarcoma recr...
Show MoreA Prospective Phase Ib/II Trial of Radiotherapy Combined With Tyrosine Kinase Inhibitor and Immune Checkpoint Inhibitor in High-Risk Localized Soft Tissue Sarcoma (IRIS)
- IRIS
- FDRT-2021-328-2631-A1
Phase 2
| Participant Group/Arm | Intervention/Treatment |
|---|---|
ExperimentalTreatment Arm There will be 52 patients with high-risk localized extremity and truncal soft tissue sarcoma recruited.
In safety lead-in phase (phase Ib): using 3+3 design, patients will receive 6 cycles of Surufatinib in three different dosages and Sintilimab. And radiotherapy will begin in week 4.
In extended phase (phase II): Surufatinib in RP2D, Sintilimab and radiotherapy will be applied as before. | Surufatinib In phase Ib: 250mg, 200mg, d1-21，qd; In phase II: recommended phase 2 dose (RP2D), d1-21，qd. Sintilimab 200mg, d1, q3w Radiotherapy BED=50-60Gy (α/β=10); Radiation dose depends on tumor characteristics and organs at risk.
Starts at the begin of the second cycle of systemic therapy (week 4 of the therapy). |
| Outcome Measure | Measure Description | Time Frame |
|---|---|---|
Objective Response Rate (ORR) | The percentage of patients with objective response. Objective response is defined as complete response (CR) or partial response (PR) per response evaluation criteria (RECIST v1.1) before surgery. | The objective response rate (ORR) will be evaluated before surgery. |
| Outcome Measure | Measure Description | Time Frame |
|---|---|---|
Pathological Complete Response (pCR) and Near pCR Rate | The proportion of subjects whose pathological response rate of tumor tissue in postoperative specimens is ≥90% after preoperative treatment. | The pathologic complete response (pCR) rate will be evaluated from surgical samples, immediately after surgery. |
Non-Perfused Volume (NPV) | The changes in tumour volume that are not enhanced in imaging images with contrast agent before and after treatment. | The non-perfused volume (NPV) will be measured in four weeks before preoperative treatment and before surgery in week18-21. |
Adverse Events | The toxic reactions are evaluated and graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events, Edition 5 (NCI-CTCAE V. 5). | From the beginning of treatment to 90 days after the end of the last treatment. |
Wound Complications | Postoperative incision healing, with reference to the Canadian study for grading of wound complications. | Up to 120 days from the surgery. |
Local Control Rate | The proportion of subjects who recurred within the radiotherapy exposure field from the start of treatment to the imaging assessment of all evaluable subjects. | From the start of treatment to local recurrence, up to 5 years. |
Progression-Free Survival (PFS) | The time from initiation of treatment to PD or death from any cause. | Up to 5 years |
Overall Survival (OS) | The time from initiation of treatment to death from any cause. | Up to 5 years |
Quality of Life (QoL) according to the Musculoskeletal Tumor Society (MSTS) | The Musculoskeletal Tumor Society (MSTS) is a measure of physical function across 7 items, including pain, range of motion, strength, joint stability, joint deformity, emotional acceptance, and overall function. Each item is scored from 0(worst) to 5(best) with a maximum possible score of 35, which is converted to a scale from 0 to 100 points | Quality of Life (QoL) will be evaluated at least five times: before treatment, at 3, 6, 12 and 24 months respectively after surgery. |
Quality of Life (QoL) according to the Toronto Extremity Salvage Score (TESS) | The Toronto Extremity Salvage Score (TESS) is a self-administered questionnaire evaluating possible limitations in physical activity. A total of 30 questions are included in the TESS, and the degree of disability is rated from 0 (complete disability) to 5 (no functional impairment) in each item | Quality of Life (QoL) will be evaluated at least five times: before treatment, at 3, 6, 12 and 24 months respectively after surgery. |
Quality of Life (QoL) according to the Short Form (SF)-36 questionnaires | The Short Form (SF)-36 questionnaires is a 36-item health survey status which is composed of the following eight domains: physical functioning, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. Each of these domains can be rated from 0 (worst) to 100 (best). The final SF-36 score is converted to a 0-100 points range scale | Quality of Life (QoL) will be evaluated at least five times: before treatment, at 3, 6, 12 and 24 months respectively after surgery. |
- Aged from 18 to 70, with life expectancy more than 2 years
- Histologically confirmed STS, G2 or G3
- Has imaging-confirmed localized lesions on the limbs or trunk without distant metastases
- Has>5 cm lesions, or the lesions are determined to be borderline resectable or unresectable by a multidisciplinary consultation.
- Experience local recurrence after surgery (disease-free survival more than 2 months after surgery) or primary tumor
- ECOG performance status 0-1
- Demonstrate adequate organ function (bone marrow, liver, kidney and clotting function) within 7 days before the first administration without using blood products or hematopoietic stimulating factors.
- Fully informed and willing to provide written informed consent for the trial
The presence of regional or distant metastases detected by imaging evaluation
The following histological types: osteosarcoma, chordoma, classic chondrosarcoma, Kaposi's sarcoma, malignant mesothelioma, radiation-induced sarcomas
History of another primary malignant tumor within the past three years or at the same time (excluding localized basal cell carcinoma, cutaneous squamous cell carcinoma, ductal carcinoma in situ, lobular carcinoma in situ, adenocarcinoma in situ of cervix, or other previous malignant tumor with a disease-free survival of more than 10 years)
Receiving any other chemotherapy or targeted therapy within 4 weeks before enrollment
Prior treatment using anti-PD1 immunotherapy
Prior radiotherapy towards the target lesion or has other contraindications to radiotherapy or surgery
Baseline laboratory indicators do not meet the following criteria: neutrophils
≥1.5×10^9/L, Hb≥90g/L, PLT≥100×10^9/L , ALT ≤2.5 ULN, AST ≤2.5 ULN, Cr≤ 1.5 ULN or creatinine clearance rate <50ml/min, TBIL ≤1.5 ULN, APTT≤1.5 ULN, PT ≤1.5 ULN
Urinary protein ≥ 2+, or 24-hour urine protein ≥1.0g/24h
Uncontrolled hypertension: SBP >140mmHg or DBP > 90mmHg
Uncontrolled hyperglycemia or coagulation disorder
Active infection requiring systemic anti-infective therapy
Uncontrolled mental diseases
Previous surgery within 2 weeks of before enrollment (excluding diagnostic biopsy or peripherally inserted central catheter implantation)
History of immunodeficiency diseases or active autoimmune disease requiring systemic treatment
Pregnant or lactating women
Allergic to any component of the therapy
Fudan University829 active studies to exploreShanghai Municipality